

PORTICO-I: Self-Expanding, Repositionable Transcatheter Heart Valve in Severe Aortic Stenosis

Prospective, single-arm, non-randomized, multicenter

Objective: To report 1-year outcomes of transcatheter aortic valve replacement (TAVR) with new self-expanding, repositionable transcatheter heart valve (THV) system.




941 Patients with severe, symptomatic aortic stenosis and high surgical risk (82.4 ± 5.9 years, 65.7% female, STS score: 5.8%) were enrolled and underwent TAVR with THV system.

Outcomes at 12 months




12.1%
All-cause mortality



6.6%
Cardiovascular mortality




2.2%
Disabling stroke



2.5%
Myocardial infarction



8.66
Mean aortic transvalvular gradient (mmHg)



2.6%
Paravalvular leakage (PVL)

TAVR with the new THV in patients at increased surgical risk is associated with low 1-year mortality and stroke rates. Favorable hemodynamic results were observed with low transvalvular pressure gradient and incidence of significant PVL.